News

Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmBH are all now operations under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.
February 22, 2021

MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership for MVX-ONCO-2 Cancer Immunotherapy

GENEVA, Switzerland and MUNICH, Germany – Feb 22, 2021 —MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy ...

January 25, 2021

Dusan Kosijer apppointed CEO of Minaris Regenerative Medicine GmbH

MUNICH, Germany – January 25, 2021- Minaris Regenerative Medicine GmbH, a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry fully owned by Showa Denko Materials Co., Ltd., announces the appointment of Dusan Kosijer as CEO of the European operations of Minaris as of January 1, 2021.

November 23, 2020

Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency

WORCESTER, Mass. and MUNICH, Germany– Nov 23, 2020 — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and ...

November 2, 2020

Minaris Regenerative Medicine to Significantly Expand Manufacturing Capacity for Cell and Gene Therapies in Germany and Japan

Munich, Germany and Yokohama, Japan – Nov. 2, 2020 — Minaris Regenerative Medicine (“Minaris”), a leading global contract development and manufacturing organization for cell and gene therapies, wholly owned by Showa Denko Materials Co., Ltd., announced today a total investment of 64.5 million USD to significantly expand its facilities in Europe and Asia.

September 23, 2020

Hitachi Chemical's Global Regenerative Medicine Business Renamed Minaris Regenerative Medicine

Allendale, NJ., USA, Munich, Germany, and Yokohama, Japan-Sept. 23, 2020-The regenerative medicine business of Hitachi Chemical Co., Ltd. (“Hitachi Chemical”) announces that, effective today, it has adopted the name Minaris Regenerative Medicine to represent its global contract development and manufacturing services business for the cell and gene therapy industry. “By working and using the single ...

May 11, 2020

Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with bluebird bio

 ALLENDALE, NJ. and MUNICH, GERMANY.-- May 11, 2020-- Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) and apceth Biopharma GmbH (apceth), both subsidiaries of Hitachi Chemical Co., Ltd. (Hitachi Chemical), today announced that they have expanded their relationship with bluebird bio (NASDAQ: BLUE) with long-term development and manufacturing services agreements for clinical and ...

April 10, 2020

Continuing to Navigate COVID-19 Together

The entire team at HCATS continues its commitment to stay ahead of and respond to the COVID-19 situation.

March 18, 2020

Navigating COVID-19 at HCATS

At HCATS, we are dedicated to providing our clients with high value development and manufacturing services while fostering a safe environment that does not put our patients, clients, or employees at risk. Due to this and the growing concern of COVID-19, we are taking necessary precautions and implementing new policies and procedures so we can continue to work toward making transformative ...

January 30, 2020

Hitachi Chemical Opens New Cell and Gene Therapy Manufacturing Facility

Company Expects to Add Up to 500 Employees in New Jersey Hitachi Chemical Advanced Therapeutics Solutions, LLC (“HCATS”), a subsidiary of Hitachi Chemical Co., Ltd. representing Hitachi Chemical’s Regenerative Medicine Business Sector (“RMBS”) in North America, today announced the opening of its new cell and gene therapy manufacturing facility in Allendale, New Jersey. The new facility is the ...

All Posts